应公司要求，股份已自2025年8月12日上午九时正起于联交所暂停买卖，以待刊发本公告。公司已向联 交所申请自2025年8月13日上午九时正起恢复股份于联交所买卖。 认购事项所得款项总额将为1亿港元，及经扣除就认购事项产生的相关开支后，公司根据认购事项应收 所得款项净额估计约为9866.18万港元。公司拟将认购事项所得款项净额用于(i)商业化产品的研发;(ii)营 销及推广活动;(iii)偿还贷款融资及借款;及(iv)集团日常营运。 智通财经APP讯，北海康成-B(01228)发布公告，于2025年8月12日(交易时段前)，公司与认购人百洋健 康产业国际商贸有限公司订立认购协议，据此，公司已有条件同意发行及认购人已有条件同意认购 7497.15万股认购股份，认购价为每股认购股份1.34港元。每股认购股份1.34港元的认购价较股份于2025 年8月11日(即最后交易日)在联交所所报的收市价每股1.67港元折让约19.76%。 ...

认购事项所得款项总额及所得款项净额将分别为约417万港元及400万港元。所得款项净额拟用于学校旅 游市场及旅游业的推广。 智通财经APP讯，飞道旅游科技(08069)发布公告，于2025年8月1日，公司拟向认购人ASPECT, Inc.配发 及发行合共1.36亿股股份，占公司经发行认购股份扩大后已发行股本约16.67%。 认购价为每股认购股 份0.0306港元，较8月1日收市价每股0.032港元折让约4.38%。 ...

中国儒意(00136)发布公告，于2025年7月31日，公司与认购方(无极资本管理有限公司)订立认购协议， 据此，认购方已有条件同意认购，而公司已有条件同意以认购价每股认购股份3.00港元发行及配发合共 13亿股认购股份;及(ii)于2025年8月1日(交易时段前)，公司与配售代理就认购事项订立配售协议，据 此，配售代理已有条件同意按尽力基准促使认购方与公司订立认购协议以按认购价认购认购股份。 认购股份相当于经配发及发行认购股份扩大的公司已发行股本(假设自本公告日期起至完成日期，除配 发及发行认购股份外，公司已发行股本概无任何变动)约7.51%。认购价为每股认购股份3.00港元，较 2025年7月31日在联交所所报每股股份收市价3.14港元折让约4.46%。 经扣除认购事项的相关配售代理费、成本及开支后，认购事项的所得款项净额合共将约为38.95亿港 元。公司拟按下列方式使用认购事项的所得款项净额：(i)20%用于集团业务的增长及扩张;(ii)60%用于 战略性投资及收购以扩大集团的业务;及(iii)20%用作一般营运资金用途(主要包括支付广告及宣传费用、 员工成本、技术及开发服务费用及租金成本)。 ...

本次配售预计筹集款项总额2215万港元，净额约为2202万港元。募集资金的用途包括：约1320万港元用 于偿还集团逾期应付的租赁款项以及在公布日期后3个月内到期的未偿还债券和其他应付款项；约880万 港元将作为集团的一般营运资金。 创业集团控股宣布，计划向沈定女士、赵素梅女士、黄智俊先生和张红兵女士（认购人）配发及发行共 计2.215亿股股份。此次发行完成后，这些股份将占公司扩大后已发行股本的约12.12%。每股认购价格 为0.10港元，较7月29日的收市价0.069港元溢价约44.93%。 （原标题：创业集团控股拟发行合共2.215亿股 净筹约2202万港元） ...

待完成后，认购事项所得款项总额及所得款项净额预计将分别约为2215万港元及2202万港元。认购事项 的所得款项净额拟定用途为：约1320万港元用作偿还集团逾期应付租赁款项及其他将于本公布日期起3 个月内到期的未偿还债券应付款项及应付租赁款项;及约880万港元用作集团一般营运资金。 创业集团控股(02221)发布公告，于2025年7月29日，公司拟向认购人(沈定女士、赵素梅女士、黄智俊先 生、张红兵女士)配发及发行合共2.215亿股认购股份，相当于公司经配发及发行认购股份扩大后之已发 行股本的约12.12%。每股认购股份的认购价为0.10港元，较7月29日收市价每股股份0.069港元溢价约 44.93%。 ...

Core Viewpoint - The company plans to issue a total of 221.5 million subscription shares, representing approximately 12.12% of the enlarged issued share capital after the issuance, at a subscription price of HKD 0.10 per share, which is a premium of about 44.93% over the closing price of HKD 0.069 on July 29 [1] Financial Summary - The total amount expected to be raised from the subscription is approximately HKD 22.15 million, with a net amount of about HKD 22.02 million [1] - The net proceeds from the subscription are intended to be used for the repayment of overdue lease payments and other outstanding bond payments due within three months from the announcement date, amounting to approximately HKD 13.2 million, and for general working capital of approximately HKD 8.8 million [1]

于7月29日根据股份购买协议拟以每股对价股份12港元的发行价格，根据一般授权分配及发行总计 198.55万股对价股份。 药师帮(09885)发布公告，于7月8日至7月29日，根据公司于2019年1月1日采纳的2019年股份激励计划， 因行使所获授予的购股权发行合共56.04万股股份。 ...

智通财经APP讯，领航医药生物科技(00399)发布公告，于2025年7月15日，本公司与认购人A张彪兵订 立认购协议A，认购人A有条件同意认购而本公司有条件同意配发及发行合共6000万股股份，认购价A 为每股认购股份A 0.312港元。认购股份A将根据一般授权配发及发行。 认购价A和认购价B较股份于2025年7月15日(即认购协议A日期)在联交所所报的收市价每股0.39港元折 让约20%。 该等认购事项所得款项总额及所得款项净额将分别为约2808万港元及2778万港元，拟用作本集团的一般 营运资金。 董事认为，考虑到近期市况对本集团而言是巩固其资本基础及财务状况的良机，透过发行认购股份筹集 资金属合理。董事认为，发行认购股份是筹集额外资金的适当途径，因为该等认购价较上文所载市价有 所折让，而此乃经本公司分别与该等认购人公平磋商后达致。 假设本公司已发行股本于本公告日期至完成期间并无变动，认购股份A占于本公告日期本公司现有全部 已发行股本约3.00%;及本公司经发行认购股份扩大后全部已发行股本约2.92%。 于2025年7月15日，本公司与认购人B陈静订立认购协议B，认购人B有条件同意认购而本公司有条件同 意 ...

Group 1 - The company announced agreements with various subscribers to issue a total of 19.34 million shares at a subscription price of approximately HKD 0.04801 per share [1] - The company also entered into agreements to issue convertible bonds amounting to HKD 15 million each to three different subscribers, with a conversion price of HKD 0.04801 per share [2] - The total gross proceeds from the subscription are approximately HKD 2.79 million, with a net amount of approximately HKD 2.52 million, which will be used to repay group debts and provide working capital [2] Group 2 - The board believes that raising funds through the subscription is reasonable given the recent market conditions, and it provides an opportunity to enhance the company's working capital and financial position [2] - The subscription not only offers fundraising opportunities but also expands the company's shareholder base and capital foundation [2]

Core Points - The company, JOINN LABORATORIES (CHINA) CO., LTD., was established on December 26, 2012, and is registered in the Beijing Economic and Technological Development Zone [2] - The company was approved by the China Securities Regulatory Commission (CSRC) to issue H shares on August 4, 2017, and subsequently listed on the Hong Kong Stock Exchange [2][3] - The registered capital of the company is RMB 749.34822 million [2][3] - The company aims to provide a new drug research and development technology platform for domestic and foreign enterprises, accelerating the industrialization of scientific and technological achievements [5] Company Structure - The company is a permanent joint-stock company, with all assets divided into equal shares, and shareholders are liable only to the extent of their subscribed shares [3] - The company has a total of 270,820,329 shares, with 63,035,301.4 million shares held by domestic investors, accounting for approximately 84.12% of the total share capital, and 11,899,520.6 million H shares held by foreign investors, accounting for approximately 15.88% [9] - The company can issue ordinary shares and, with approval, can also issue other types of shares [6][9] Share Issuance and Management - The company issues shares based on principles of openness, fairness, and justice, ensuring that each share of the same type has equal rights [6] - The company can increase its capital through various methods, including public offerings, private placements, and bonus shares [10] - The company has the right to repurchase its shares under specific circumstances, such as reducing registered capital or merging with other companies [11][12] Shareholder Rights - Shareholders have the right to receive dividends, attend and vote at shareholder meetings, supervise the company's operations, and transfer their shares [28] - The company must maintain a shareholder register that includes details of each shareholder and their respective shareholdings [22][25] - Shareholders can request the company to repurchase their shares if they disagree with resolutions made at shareholder meetings [28]